CLBS is "Spending to Deliver a Flawed Product" - Dawson James Reiterates Caladrius Biosciences (CLBS) at Neutral, Maintains Skeptical Tone
Tweet Send to a Friend
Dawson James analyst Jason Kolbert reiterated a Neutral rating on Caladrius Biosciences (NASDAQ: CLBS). The analyst comments: "Caladrius continues to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
